Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
4,193 people get QCOR articles and Market Currents by email alert.
Get email alerts on QCOR »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
PR Newswire (May 8, 2013)
-
-
-
-
-
PR Newswire (Apr 30, 2013)
-
-
-
-
-
-
PR Newswire (Apr 15, 2013)
-
-
-
-
PR Newswire (May 8, 2013)
-
at CNBC.com (Apr 30, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 15, 2013)
-
at CNBC.com (Mar 6, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
PR Newswire (Jan 2, 2013)
-
at MarketWatch.com (Dec 27, 2012)
-
PR Newswire (Dec 4, 2012)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Dec 3, 2012)
-
at CNBC.com (Nov 29, 2012)
-
PR Newswire (Oct 23, 2012)
-
PR Newswire (Oct 15, 2012)
-
at CNBC.com (Oct 9, 2012)
-
at CNBC.com (Oct 8, 2012)
QCOR vs. ETF Alternatives
Company Description
We market H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”), and the treatment of nephrotic syndrome.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, November 2, 2012, 12:52 PM Cerium Pharmaceuticals Synacthen, a treatment for infantile spasms, is no threat to Questcor's (QCOR -7.3%) Acthar for a number of reasons, says PropThink's David Moskowitz. First, the drug is known to contain benzyl alcohol which has been implicated in infant toxicity, and FDA approval for a product containing this ingredient in infants is highly unlikely. Second, QCOR's Acthar Gel already has Orphan Drug status with an exclusivity for infantile spasms that doesn't expire until 2017. Lastly, infantile spasms represent only a small fraction of Acthar sales, so it would have minimal impact. 1 Comment [Healthcare, On the Move]
- Friday, November 2, 2012, 12:39 PM Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a synthetic version of Acthar had been approved by the FDA, rather than the Orphan Drug Designation it had actually been given, according to a Seeking Alpha contributor. The errant headline has since been pulled and refiled to reflect the correction, but the hangover in the shares continues in mid-day trading nontheless. 6 Comments [Healthcare, On the Move]
- Friday, November 2, 2012, 12:04 PM Questcor Pharmaceuticals (QCOR -7.3%) takes a hit today on reports that Cerium Pharmaceuticals has been granted an FDA orphan drug designation for Synacthen Depot, a synthetic equivalent of Acthar. 21 Comments [Healthcare, On the Move]
- Tuesday, October 23, 2012, 4:08 PM Questcor (QCOR): Q3 EPS of $0.91 beats by $0.14. Revenue of $140.3M beats by $11M. (PR) 21 Comments [Healthcare, Earnings]
- Tuesday, October 23, 2012, 12:10 AM Notable earnings after Tuesday’s close: ACE, AFL, ALTR, AMGN, BCR, BNNY, BRCM, BWLD, CBI, CHRW, FB, FBC, FBHS, FTI, GILD, HTS, ILMN, INVN, IRBT, JNPR, NBR, NFLX, NFX, NSC, PLCM, PNRA, QCOR, RFMD, STM, TPX, TSS, UIS, VMW, WYNN Comment! [Earnings]
- Monday, October 22, 2012, 5:35 PM Notable earnings after Tuesday’s close: ACE, AFL, ALTR, AMGN, BCR, BNNY, BRCM, BWLD, CBI, CHRW, FB, FBC, FBHS, FTI, GILD, HTS, ILMN, INVN, IRBT, JNPR, NBR, NFLX, NFX, NSC, PLCM, PNRA, QCOR, RFMD, STM, TPX, TSS, UIS, VMW, WYNN Comment! [Earnings]
- Friday, October 19, 2012, 1:44 PM Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to a Citron Research report. The short seller is now claiming that Humana (HUM -1.5%) has issued a new Commercial Preauthorization document containing a new, specifically asterisked preauthorization for reimbursement for Acthar, which it contends is part of a pattern of insurers taking a more restrictive stance on authorization policy with regard to the drug's reimbursement. 40 Comments [Healthcare, On the Move]
- Tuesday, October 16, 2012, 10:24 AM Shares of Questcor (QCOR +6.7% are rallying this morning after James Flynn of Deerfield Management reported a 5.82% passive stake in the company late yesterday. 3 Comments [Healthcare, On the Move]
- Tuesday, October 9, 2012, 1:28 PM Heavily-shorted Questcor (QCOR +6.1%) surges after receiving more positive sell-side commentary (previous), this time from Jefferies, which is upgrading shares to Buy. Analyst Biren Amin believes investors are pricing Questcor as if almost no insurers will provide coverage for its Acthar gel for treating nephrotic syndrome or MS, something he considers unrealistic. 1 Comment [Healthcare, On the Move, Quick Ideas]
-
Tuesday, October 9, 2012, 9:10 AM
Premarket gainers: RSH +11%. EMXX +10%. QCOR +7%. NAVB +6%.
Losers: EW -17%. ATHX -14%. OC -7%. NFLX -7%. ALU -5%. 3 Comments [On the Move] - Monday, October 8, 2012, 9:39 AM Questcor (QCOR +2.3%) rallies after SunTrust and Lazard respond positively to a UnitedHealth/Oxford policy update letter (.pdf) regarding Acthar gel coverage, which produced a selloff on Friday. SunTrust argues the update should reassure investors Acthar has value in treating nephrology and MS, while Lazard claims it's a positive given investor fears following Aetna's move to limit coverage. 40.3% of Questcor's float was shorted as of Sep. 14. 1 Comment [Healthcare, On the Move, Quick Ideas]
- Friday, October 5, 2012, 1:37 PM Questcor (QCOR -4%) trades lower after United Healthcare's Oxford Policy Update publishes revised Acthar approval timeframes , which limits the use of QCOR's Acthar Gel. 18 Comments [Healthcare, On the Move]
- Friday, September 28, 2012, 3:15 PM Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. 8 Comments [Healthcare]
-
Friday, September 28, 2012, 9:10 AM
Premarket gainers: BYFC +42.86%. CYTX +18.91%. RIMM +15.83%. ASTX +8.71%. QCOR +9.03%.
Losers: ADTN -8.14%. CLWR -7.43%. PPHM -5.41%. 2 Comments - Friday, September 28, 2012, 8:36 AM Questcor Pharmaceuticals (QCOR) declares its first-ever quarterly dividend of $0.20/share. Forward yield 4.48%. For shareholders of record Oct 31. Payable Nov 15. Ex-div date Oct 29. Shares +8% premarket. (PR) 4 Comments [Dividends, On the Move]
-
Monday, September 24, 2012, 12:45 PM
Midday top 10 gainers: LMLP +82%. LPH +28%. BCOM +20%. RMBS +20%. SKBI +19%. VII +18%. AUDC +17%. CHOP +16%. COGO +15%. RMKR +13%.
Top 10 Losers: PPHM -77%. QCOR -33%. DLGC -15%. PAMT -12%. BIOF -11%. DHRM -11%. VECO -11%. CCM -10%. SRI -10%. BONA -10%. Comment! [On the Move]
-
Dividend Sheet
$LTC $QCOR and $HRL are tomorrow's top yielding ex-dividend stocks - http://stks.co/t8n1 - 5 shares with 2.94% average yield - View all 0 replies
-
- View all 0 replies
-
- View all 10 replies
-
techwonk: ...use your own judgment whether to hold or exit and re-enter... -
oneotherfool: It hasn't dipped below $25 since Dec. It's possible but I doubt it. I plan on holding & buying more below $27. Let's c what happens next wk.
-
oneotherfool
In a little over 2 weeks, $QCOR is down more than 14% for no real reasons. It's as if the great earning results never happened...load more? - View all 6 replies
-
Michael Webb: And in the further chance that additional fallout comes in the form of insurance companies rethinking reimbursement schedules, reason enuff? -
Michael Webb: Will these things happen? Probably not! BUT THAT IS WHY THE STOCK IS STUCK AT $32. Sorry. But that's the reason.
-
- View all 0 replies
-
- View all 5 replies
-
-
SKS1586: techwonk: Results are good with Joel Greenblatt's MFI Stocks (Warren Buffett Formula). Magic Diligence works exclusively with these stocks.
-
- View all 9 replies
-
PeterScriabin: you go to QCOR YMB (Yahoo Message Board) search on above terms, look for mikeylikesit33_99 posts = Michael Fuller. I did say "rumors" above. -
PeterScriabin: If we're talking $QCOR, have to assume we understand basics. Suggest reading posts of Maxdad, PharmaMan58, mikey. Way better YMB than most.
-
- View all 2 replies
-
gethigh: Yeah...plenty of shorts that have to cover. I'm still holding... -
-
StockConsultant
$QCOR getting close to a breakout above 33.55 with a good sized resistance gap, stock charts and analysis http://goo.gl/tPcK4 - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 4 replies
-
eliaa123: I think it's because of insider action from a few days back. http://on.mktw.net/TrNZzF. He got in @5 and that's not all his $QCOR stock -
-
TruffelPig
What is the best options strategy to capture big movement in a stock up and down? Looking at $QCOR. - View all 6 replies
-
eliaa123: could you give an example of an options strategy that you would use here?
-
conspicuous consumer: I bought a couple of long calls with a $25 strike back when QCOR was trading around $20. Sold them yesterday for a nice profit.
-
- View all 10 replies
-
Jay094: Ok, is anyone looking at (TRU) ? Am I crazy or am I looking at this correctly ? Shows share price selling for .62 cents per share but..?
-
Jay094: The dividend is paying .68 cents per share ? So, I buy into these shares at a profit of .06 cents per share ?
-
- View all 3 replies
-
vireoman: Now it has been priced in twice. I'm going to wait for negative volume to peter out before opening a position. -
eliaa123: so far the fearlessness hasn't paid off. bad news appears to spread like wildfire, even if it's old news...
-
- View all 5 replies
-
-
-
- View all 5 replies
-
Paulo Santos: No opinion there. It's not actually a "market" either. It's more like the "long term Fed liquidity facility" ... eheh
-
-
- View all 10 replies
-
tatensolo: Insurance issue overblown. DOJ investigation limited to DA of eastern PA, known for going after pharmas. This is a solid undervalued co.
-
-
- View all 1 replies
-
-
- View all 1 replies
-
wecap: this stock is killing me. My Nov Calls sucking bug time. Should be a sec investigation. Shorts are spreading false rumors
-
- View all 6 replies
-
piggysun: Volume is very light, no worries. The upcoming conference might push it to 30
-
-
- View all 17 replies
-
TruffelPig: Looks like shorts are getting desperate. Someone made a ton of $$ on puts again. Hello SEC, where are you?
-
-
- View all 3 replies
-
eliaa123: The stock is so volatile that bad news travels like a wildfire. Two positive analyst actions this morning. ValuEngine and Leerink Swann.
-
gethigh: Just too bad good news is considered a par while any bad "news" (emphasis on the "") is a triple bogey.
-
- View all 11 replies
-
-
-
FortSumter
Was at the gym and thought I saw QCOR at $58. Turned out it was QCOM. For a moment there I was in heaven. Ever happen to anyone else? - View all 4 replies
-
-
-
- View all 3 replies
-
-
Michael Webb: 30 is a nice target for year end. QCOR didn't help ease investor fears by eliminating monthly reports of product sales opting for quarterly